12 Dec 2013, 10:55 am
This comes after GSK lobbied the UK Government for the tax scheme which reduces the rate of corporation tax due on incomes derived from patents. The desired effect of this scheme was to encourage investment in research and development and innovation, an objective which GSK claims has been successful.
Roger Connor, GSK’s President of Global Manufacturing and Supply, said: “The establishment of the patent box has transformed how we see the UK as a place to invest. As a result, last year we announced we were building our first new factory in the UK for 40 years. The investments announced today are in addition to that and will allow us to harness new technologies that have the potential to deliver a step-change in how we make medicines."
More from Out-Law.com
